Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4578 Phase 1 Study in First-Line Colorectal Cancer
NCT06547385Phase 1Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Jan 2021
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ONO-4578 in colorectal cancer (CRC) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Incidence and severity of Adverse Events and Serious Adverse Events up to 3 years, Incidence and severity of clinical laboratory abnormalities up to 3 years and 7 more. Started Jan 2021; status: active, not recruiting.
02
Drugs
ONO-4578
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06547385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06547385.